These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 10526196

  • 1. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, Gasperini C, Fieschi C, Dianzani F.
    J Neurol Sci; 1999 Oct 15; 168(2):131-6. PubMed ID: 10526196
    [Abstract] [Full Text] [Related]

  • 2. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
    Kivisäkk P, Alm GV, Fredrikson S, Link H.
    Eur J Neurol; 2000 Jan 15; 7(1):27-34. PubMed ID: 10809912
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
    Zare N, Zarkesh-Esfahani SH, Gharagozloo M, Shaygannejad V.
    J Korean Med Sci; 2013 Dec 15; 28(12):1801-6. PubMed ID: 24339712
    [Abstract] [Full Text] [Related]

  • 10. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
    Ferrarini AM, Sivieri S, Buttarello M, Facchinetti A, Perini P, Gallo P.
    Mult Scler; 1998 Jun 15; 4(3):174-7. PubMed ID: 9762669
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P, Calabrese M, Biasi G, Gallo P.
    J Neurol; 2004 Mar 15; 251(3):305-9. PubMed ID: 15015010
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J, White R.
    Mult Scler; 1997 Dec 15; 3(6):402. PubMed ID: 9493643
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.